Myasthenia gravis is an autoimmune disorder that affects muscular tissues of the human body. The disease occurs when immune system of the body produces antibodies, which influence the interaction between nerves and muscles, hence affecting the functioning of normal muscular tissues. Treatment options for myasthenia gravis are disease-modifying medicines, immunosuppression, and thymectomy. According to the German Myasthenia Gravis Association, approximately 1,230 to 1,530 people residing in Germany suffer from myasthenia gravis.
The Germany myasthenia gravis treatment market is segmented by drug class, age group, and distribution channel. On the basis of drug class, the market is divided into intravenous immunoglobulin, monoclonal antibodies, and others. As per age group, it is bifurcated into below 55 years and above 55 years. Depending on distribution channel, the market is classified into hospital pharmacies, drug store & retail pharmacies, and online providers.
Federal government and private companies in Germany are taking initiatives to increase awareness about myasthenia gravis, help individuals obtain suitable treatment & medications, and offer support to patients & their families. These initiatives have driven the development of the Germany myasthenia gravis treatment market. Monoclonal antibodies are significantly used to treat myasthenia gravis, since their effectiveness has been exhibited by numerous clinical trials. This is attributed to their higher strength and simple usage, as compared to other immunosuppressive medicines.
In addition, advanced diagnostic techniques such as electrophysiological and serological testing play crucial function in the medical diagnosis of myasthenia gravis. Advancements in techniques have made diagnosis procedures more precise, quick, reliable, and affordable. This has boosted the demand for medical diagnoses, therefore, driving the market growth.
However, the cost of treatment for myasthenia gravis is extremely expensive for many people in Germany. High expense of medicines and diagnoses such as monoclonal antibodies, electromyography, and MRI scans limits numerous people from gaining access.
Despite significant improvements in diagnosis strategies and accessibility of drugs for treatment of myasthenia gravis, the market growth is restrained due to shortage of technicians and lack of sufficient medical diagnosis centers in Germany. This affects identification of actual number of individuals suffering from the disease, thereby confining them from receiving proper treatment. Furthermore, numerous therapies available for myasthenia gravis, such as immunosuppressants, have various side effects such as surge in risk of infection and inability to conceive. This prevents numerous individuals from taking up such therapies, thereby hampering the development of the market.
On the contrary, numerous new immunosuppressive drugs such as rituximab and abatacept have been produced recently. These drugs have the potential to offer better recovery to patients suffering from myasthenia gravis as compared to existing therapies. Businesses such as Novartis and Pfizer have spent notably in drug discovery, therefore, creating significant opportunities for the market growth.
There has been surge in the number of scientific trials being performed in Germany for the advancement of novel drugs and therapies for myasthenia gravis. This has increased awareness regarding the illness and has offered several opportunities for the growth of the Germany myasthenia gravis treatment market.
In addition, Non-Governmental Organizations (NGOs) are considerably being established in Germany to offer education & learning, understanding, and support to people suffering from myasthenia gravis. Formation of such organizations has increased the number of patients receiving necessary therapy and medicines. This has driven the growth of the Germany myasthenia gravis treatment market. Furthermore, personalized therapies have gained popularity among individuals suffering from myasthenia gravis, owing to the treatment method using precision medicine. This popularity has been attributed to the enhanced recovery received by patients.
Breakout of COVID-19 pandemic resulted in various modifications in the functioning of health care sector. Several hospitals adopted telehealth, which has proved to be advantageous for individuals with myasthenia gravis as it offers timely consultation and better treatment & medications.
The myasthenia gravis treatment market is segmented into drug class, and distribution channel. In terms of drug class, it is bifurcated into monoclonal antibodies, intravenous immunoglobulin, others. Based on the distribution channel, below 55 Years, above 55 Years
Key players profiled in the report are Bayer, Biogen, Tocagen, Roche Holding AG, Merck, Sanofi, Novartis, Eisai Co. Ltd., Alexion Pharmaceuticals, Teva Pharmaceuticals.
Key Benefits For Stakeholders
- Enable informed decision-making process and offer market analysis based on current market situation and estimated future trends.
- Analyze the key strategies adopted by major market players in Germany Myasthenia Gravis Treatment Market.
- Assess and rank the top factors that are expected to affect the growth of Germany Myasthenia GravisTreatment Market.
- Top Player positioning provides a clear understanding of the present position of market players.
- Detailed analysis of the Germany Myasthenia Gravis Treatment Market segmentation assists to determine the prevailing market opportunities.
- Identify key investment pockets for various offerings in the market.
Germany Myasthenia Gravis Treatment Market Report Highlights
| Aspects | Details |
 Forecast period | 2022 - 2032 |
 Report Pages | 86 |
 By Age group |
|
 By Drug class |
|
 By Distribution channel |
|
 Key Market Players | Biogen, Bayer, Sanofi, Merck, Teva Pharmaceuticals, Eisai Co. Ltd., Roche Holding AG, Novartis, Alexion Pharmaceuticals, Tocagen |
The Germany Myasthenia Gravis Treatment Market is estimated to reach $155.4 million by 2032
Company 1, Company 10, Company 2, Company 3, Company 4, Company 5, Company 6, Company 7, Company 8, Company 9 are the leading players in Germany Myasthenia Gravis Treatment Market
1. Enable informed decision-making process and offer market analysis based on current market situation and estimated future trends.
2. Analyze the key strategies adopted by major market players in germany myasthenia gravis treatment market.
3. Assess and rank the top factors that are expected to affect the growth of germany myasthenia gravis treatment market.
4. Top Player positioning provides a clear understanding of the present position of market players.
5. Detailed analysis of the germany myasthenia gravis treatment market segmentation assists to determine the prevailing market opportunities.
6. Identify key investment pockets for various offerings in the market.
Germany Myasthenia Gravis Treatment Market is classified as by drug class, by age group, by distribution channel
Loading Table Of Content...
Loading Research Methodology...
